Valuation: Halozyme Therapeutics, Inc.

Market Cap 9.76B 8.48B 7.92B 7.27B 13.71B 930B 13.94B 93.36B 36.57B 464B 36.65B 35.84B 1,530B P/E 2026 *
12.3x
P/E 2027 * 9.47x
Enterprise Value 11.08B 9.63B 8.99B 8.25B 15.56B 1,056B 15.83B 106B 41.52B 527B 41.62B 40.7B 1,737B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 4.97x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day-0.17%
1 week-1.28%
Current month-0.19%
1 month+1.98%
3 months+27.58%
6 months+5.71%
Current year+22.41%
1 week 81.21
Extreme 81.21
83.96
1 month 73.89
Extreme 73.8901
84.44
Current year 61.32
Extreme 61.325
84.44
1 year 59.38
Extreme 59.38
84.44
3 years 32.83
Extreme 32.83
84.44
5 years 29.85
Extreme 29.85
84.44
10 years 8.18
Extreme 8.18
84.44
Manager TitleAgeSince
Chief Executive Officer 63 2014-01-05
Director of Finance/CFO 61 2013-04-30
Director of Finance/CFO - 2026-06-07
Director TitleAgeSince
Director/Board Member 59 2013-03-27
Director/Board Member 63 2014-01-05
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Fiscal year

Chief Executive Officer

5,769 0.0049%
7/1/26 Free

Executive/Senior Manager

56,055 0.0473%
7/1/26 Free

Chief Financial Officer

168,986 0.1425%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-1.28%+37.32%+94.25% 9.76B
+0.50%-2.83%+60.39%+21.99% 316B
+1.68%+0.49%+33.96%-10.30% 71.26B
-2.52%-7.68%-4.39%-6.32% 8.4B
-0.76%-4.27%-16.42%-17.04% 4.29B
+0.14%+2.22%-34.69%+5.14% 3.83B
-2.35%-7.01%-14.99%+13.53% 3.5B
-3.05%-6.64%+20.27%+38.47% 2.68B
+0.47%+6.57%+0.22%-2.10% 2.26B
+0.90%+3.00%-21.69%-14.72% 1.77B
Average -0.49%+0.20%+6.00%+12.29% 42.33B
Weighted average by Cap. +0.60%-1.67%+50.95%+16.86%

Financials

2026 *2027 *
Net sales 1.77B 1.54B 1.43B 1.32B 2.48B 168B 2.53B 16.91B 6.62B 84.02B 6.64B 6.49B 277B 2B 1.74B 1.63B 1.49B 2.82B 191B 2.86B 19.18B 7.51B 95.28B 7.53B 7.36B 314B
Net income 812M 706M 659M 605M 1.14B 77.4B 1.16B 7.77B 3.04B 38.6B 3.05B 2.98B 127B 1.03B 899M 839M 770M 1.45B 98.57B 1.48B 9.89B 3.88B 49.16B 3.88B 3.8B 162B
Net Debt 1.32B 1.15B 1.07B 985M 1.86B 126B 1.89B 12.65B 4.96B 62.86B 4.97B 4.86B 207B 205M 178M 166M 153M 288M 19.53B 293M 1.96B 768M 9.74B 769M 752M 32.12B
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
26-08-04 US$82.27 -0.01% 102,066
26-08-03 US$82.27 -0.33% 1,367,693
26-07-31 US$82.54 -0.91% 1,565,028
26-07-30 US$83.30 +0.02% 2,135,849
26-07-29 US$83.28 -0.20% 1,634,260
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
82.27USD
Average target price
86.89USD
Spread / Average Target
+5.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HALO Stock